Additionally, testosterone promotes melanoma proliferation through the activation of ZIP9.461 The classic FDA-approved androgen receptor inhibitor bicalutamide also inhibits ZIP9, thus the antagonist of the tumor-promoting role of testosterone in melanoma,461 suggesting that ZIP9 may be an effective target for melanoma and other cancers. This evidence concerns the gene SLC39A9 and cancer.